TransMedics exec sells 2,966 shares to cover taxes

TransMedics Group executive Nicholas Corcoran reported share transactions linked to restricted stock unit vesting.

Rhea-AI Filing Summary

TransMedics Group executive Nicholas Corcoran reported share transactions linked to restricted stock unit vesting. On March 2, 2026, he executed an open-market sale of 2,966 shares of common stock at $139.12 per share, leaving him with 29,831 shares held directly.

Earlier, on January 23, 2026, 984 shares at $135.30 per share were disposed of to satisfy tax withholding obligations upon RSU vesting. Footnotes state both the issuer’s share withholding and the “sell to cover” sale were required to cover Corcoran’s tax liabilities tied to these equity awards.

Insider Trade Summary

Net Seller: 2,966 shares

Net Sell 2 txns

Insider Corcoran Nicholas

Role See remarks

Sold 2,966 shs ($413K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,966	$139.12	$413K
Exercise Price or Tax Liability	Common Stock	984	$135.30	$133K

Holdings After Transaction: Common Stock — 29,831 shares (Direct)

Footnotes (2)

1. F1. Shares withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units on January 23, 2026.
2. F2. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nicholas Corcoran report for TransMedics Group (TMDX)?

Nicholas Corcoran reported two share disposals related to restricted stock unit vesting. One was an open-market sale, and the other a tax-withholding transaction, both undertaken to cover tax liabilities tied to his equity compensation awards.

How many TransMedics (TMDX) shares did Nicholas Corcoran sell in the open market?

Corcoran sold 2,966 shares of TransMedics common stock in an open-market transaction. The sale occurred at a price of $139.12 per share and was described as a required “sell to cover” to satisfy tax withholding obligations from restricted stock unit vesting.

At what prices were Nicholas Corcoran’s recent TransMedics (TMDX) transactions executed?

The open-market sale of 2,966 TransMedics shares was executed at $139.12 per share. A separate tax-withholding disposition of 984 shares tied to RSU vesting was priced at $135.30 per share, according to the reported transaction details and accompanying footnotes.

How many TransMedics (TMDX) shares does Nicholas Corcoran hold after these transactions?

After the March 2, 2026 open-market sale, Nicholas Corcoran directly holds 29,831 TransMedics common shares. This figure reflects his position following the 2,966-share sale that was executed to cover tax withholding obligations on recently vested restricted stock units.

Were Nicholas Corcoran’s TransMedics (TMDX) share sales discretionary or for tax withholding?

Both transactions were tied to tax obligations from restricted stock unit vesting. Footnotes explain that 984 shares were withheld by the issuer and 2,966 shares were sold via a “sell to cover” transaction to satisfy Corcoran’s tax withholding liabilities.

What does a Form 4 tax-withholding disposition mean for TransMedics (TMDX) insiders?

A tax-withholding disposition on Form 4 generally indicates shares were withheld or sold to pay taxes on vested equity awards. For TransMedics, Corcoran’s 984-share disposition and 2,966-share sell-to-cover sale were both described as required to meet RSU-related tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 08:40 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corcoran Nicholas

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MA 01810

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		F		984(1)	D	$135.3	32,797	D
Common Stock	03/02/2026		S(2)		2,966	D	$139.12	29,831	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units on January 23, 2026.

2. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.

Remarks:

SVP of Supply Chain and Operations

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.